Physician profile
Dana Jeng
NPI 1396728309
$6,790.35
in general payments reported to CMS, 2019-2025
27 companies · $1,518 in 2025
The $1,518 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $442 · 2020: $152 · 2021: $254 · 2022: $1,614 · 2023: $1,422 · 2024: $1,389 · 2025: $1,518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,143 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,143.28 |
| Education | $184.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,068.64 | 2019-2025 | |
| Janssen Biotech, INC. | $938.51 | 2020-2025 | Tremfya, Simponi Aria |
| Galderma Laboratories, L.P. | $814.45 | 2019-2024 | Aklief, Oracea, Epsolay |
| Sun Pharmaceutical Industries INC. | $580.91 | 2021-2025 | Absorica Ld, Winlevi, Blu-U |
| Amgen INC. | $563.42 | 2022-2025 | Otezla, Otezla |
| Genzyme Corporation | $554.08 | 2022-2025 | |
| Journey Medical Corporation | $297.87 | 2022-2025 | |
| Ucb, INC. | $283.55 | 2022-2025 | Bimzelx, Cimzia |
| Merz North America, INC. | $214.52 | 2019-2025 | |
| Incyte Corporation | $187.06 | 2022-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $165.64 | 2022-2025 | Dupixent |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $164.49 | 2022-2025 | Cabtreo, Arazlo, Siliq |
| E.R. Squibb & Sons, L.L.C. | $148.70 | 2023-2024 | Sotyktu |
| Pfizer INC. | $105.55 | 2022-2023 | |
| Lilly USA, LLC | $99.68 | 2022-2024 | Taltz, Olumiant |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $91.31 | 2022-2025 | |
| Mayne Pharma Commercial LLC | $82.88 | 2022-2023 | |
| Dermavant Sciences, INC. | $81.11 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $56.69 | 2024-2025 | Zoryve |
| Organon LLC | $54.65 | 2025 | Vtama |
| Botanix Sb INC | $49.92 | 2025 | Sofdra |
| Epi Health, LLC | $44.36 | 2022 | |
| Biofrontera INC. | $44.13 | 2023-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Almirall LLC | $43.89 | 2020-2022 | |
| Medimetriks Pharmaceuticals, INC. | $22.46 | 2022 | |
| Lnhc, INC | $17.79 | 2025 | Zelsuvmi |
| Janssen Scientific Affairs, LLC | $14.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Jeng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.